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Abstract
Background: Due to low adherence to treatment and side effects of pharmacotherapy, using new brain stimulation, such as tran-
scranial direct current stimulation (tDCS) in patients with anxiety disorders are available.
Objectives: The present research was performed to evaluate the efficacy of tDCS and compare it with pharmacotherapy on reduction
of worry, depression, and anxiety in a group of Iranian patients with generalized anxiety disorder (GAD).
Methods: This study was a quasi-experimental research. A total of 18 patients (46% females and 64% males) with GAD were randomly
assigned either to tDCS, pharmacotherapy or sham conditions. Stimulation was delivered over the contralateral deltoid at 2 m/A
during 20 minutes in 10 sessions of 4 weeks. Symptoms were assessed by a 7-item GAD scale, HARS, HDRS, and PSWQ in pre-test,
post-test and follow up assessment (2 months later). Analysis of variance with repeated measure was used to analyze the data.
Results: The results showed that both tDCS and pharmacotherapy were effective in reducing worry symptoms, also the pharma-
cotherapy group compared with the tDCS group and sham condition was more effective in treating of worry. Anxiety symptoms
were reduced by both tDCS and pharmacotherapy and the difference between the 2 methods was not significant. Finally, the effec-
tiveness of tDCS therapy on reducing depressive symptoms was more significant than pharmacotherapy.
Conclusions: The tDCS is a promising treatment for generalized anxiety disorder, especially in depressive and worry symptoms.
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1. Background
Generalized anxiety disorder, as a chronic disease, is
characterized by uncontrollable sense of worry about ev-
ery aspect of life, physiological symptoms, such as sleep
disturbances, muscle tension, irritability, and problem in
concentration (1). Prevalence of this disorder has been re-
ported as 4% to 6% (2, 3) in the general population and up
to 10% in clinical treatment settings (4). Individuals with
GAD have high functional impairment (5, 6) and low qual-
ity of life (7).
Both pharmacotherapy and psychotherapy exist for
treatment of this disease, yet due to resistance to treat-
ment, low adherence of therapy and adverse side effects,
a few of these patients respond to pharmacotherapy (8).
Therefore, noninvasive brain stimulation, such as transcra-
nial direct current stimulation (tDCS) as a vigorous and
convenient technique to moderate brain activity, is now
available to treat many psychological disorders, such as
obsessive-compulsive disorder (9-12), depression (13), and
schizophrenia (14). Nevertheless, a few studies on the ef-
fectiveness of tDCS on reduction of symptoms of GAD are
available. In one research conducted by Shiozawa (15), with
positioning of the cathode on right dorsolatral prefrontal
cortex RDLPFC and the anode on contralateral deltoid, anx-
iety symptoms were improved during a 15-day treatment
course. The present research used anodal stimulation tar-
geting contralateral deltoid and cathodal stimulation on
F4 as done in previous research (15). The reason for the
use of F4 in cathodal stimulation was its activation during
functional neuroimaging (16).
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The aim of the present research was to conduct an ex-
perimental design using tDCS on reduction of depressive
and anxiety symptoms, and worry in patients with GAD.
Three major hypotheses were followed from the above
aim. Hypothesis 1 stated that tDCS has effective therapeu-
tic influence on reduction of worry. Hypothesis 2 stated
that tDCS has effective therapeutic influence on reduction
of depressive symptoms. Hypothesis 3 stated that tDCS
has effective therapeutic influence on reduction of anxi-
ety symptoms. Finally, the fundamental question of the
present research was whether there was a difference in re-
duction of symptoms between tDCS and pharmacother-
apy.
2. Objectives
The present research was performed to test the above
hypotheses and respond to the question regarding Iranian
samples. To do so, a single-blind, randomized clinical trial
with sham condition was undertaken.
3. Materials andMethods
The present research was quasi experimental, single
blind with pre-test, post-test, and follows up assessment (2
months later). A total of 18 patients with generalized anx-
iety disorder diagnosed by a psychiatrist, participated in
this study and were paired according to their age, gender,
education, severity, and duration of disease. They were ran-
domly assigned to 2 experimental groups (one with tDCS
and the other with pharmacotherapy) and one sham con-
dition. In the tDCS group, subjects received anode elec-
trode on the contralateral deltoid and cathode electrode
on the right prefrontal cortex (F4). The mean age of sub-
jects was 28.7 (SD = 9.6). Inclusion and exclusion criteria of
the patients were as follows:
3.1. Inclusion Criteria
1- Diagnosis by a psychiatrist according to diagnostic
and statistical manual of mental disorders- fifth edition
(DSM-V).
2- No previous mental illness.
3- No psychological medication.
4- Age of 18 to 55 years old.
5- No brain injury.
6- Five points or higher in the 7-item GAD scale.
3.2. Exclusion Criteria
1- Drug abuse.
2- Current physical or psychological illness, such as
schizophrenia, bipolar, and other anxiety disorders.
3- Use of medication.
Subjects were randomly assigned to 3 groups of tDCS
(6 subjects), pharmacotherapy (6 subjects), and sham con-
dition (6 subjects). This study was carried out according to
the the declaration of Hesinki-Ethical principles for Med-
ical research involving human subjects. Written consents
were obtained from all participants. It is important to note
that sham condition received tDCS treatment after follow
up assessment.
3.3. Measures
Hamilton anxiety rating scale (HARS) is a 14-item scale
that covers 13 symptoms of anxiety developed by Hamil-
ton (17). Each item was rated on a 4-point scale (0 = not
present to 4 = severe). The score range was 0 to 56. Those
who scored 5 or less were considered as having no anxiety.
Other categories were as follows: 6 to 14 = mild anxiety; 15
to 28 = moderate anxiety; 29 to 42 = severe anxiety, and 43
to 56 = very severe anxiety. In Iran, HARS was validated by
Kavyani, Mossavi and Mohit (18), and was reported to have
high reliability and validity.
Hamilton depression rating scale (HDRS) is a 17-item as-
sessment of depression over the past week developed by
Hamilton (19). The cut-off points for different levels of de-
pression were as follows: 0 to 6 = not depressed; 7 to 17 =
mildly depressed; 18 to 24 = moderately depressed; and 25
to 64 = severely depressed (20). Carnerio, Fernandes, and
Moreno, reported adequate reliability (a = 0.83) and valid-
ity for this scale (21). In Iran, Mokhber, Azar Pajooh, and As-
gharipour (22) reported the reliability of this scale via cor-
relation with BDI as 0.90 and high validity.
Penn state worry questionnaire (PSWQ) is a 16-item
scale, which was used to measure individual differences in
worry. All items were rated on a 5-point Likert type scale
from 1 (not at all typical of me) to 5 (very typical of me).
High internal consistency and test-retest reliability were
reported (23, 24). Cronbach’s alpha for this scale in the
present study was 0.90. In Iran, Cronbach’s alpha and test-
retest reliability was respectively 0.88 and 0.79. Also, the
correlation coefficient with trait anxiety and depression
was 0.68 and 0.43, which indicated high reliability and va-
lidity (25).
3.4. Statistical Analysis
All data were analyzed using the SPSS software version
22. Analysis of variance with repeated measures were used
to examine the effectiveness of pharmacotherapy and tDCS
2 Iran J Psychiatry Behav Sci. 2018; 12(2):e11071.
Sadeghi Movahed F et al.
on the research variables (worry, anxiety and depression)
and also Scheffe follow up test was used to compare the
level of effectiveness of these 2 methods.
4. Results
Descriptive statistics of worry, depression, and anxiety
scores in 3 stages of treatment was analyzed using mean
and standard deviations that are summarized in Figure 1
and Table 1. Inferential results using Analysis of Variance
(ANOVA) with repeated measure are shown in Table 2.
In order to analyze the hypotheses of the research,
analysis of variance with repeated measures was used. Be-
fore analyzing the data, Kolmogorov-Smirnov for examin-
ing the normality of data distribution, Leven test for homo-
geneity of variance, and M-box Matrix variance-covariance
were used. In each analysis, the results of Kolmogorov-
Smirnov test showed that the P value was more than 0.05.
In Leven’s test, the hypothesis of equality of variances was
met. Finally, the M-box test showed that homogeneity of
variance and covariance was fulfilled. The results of worry,
depression, and anxiety scores in treatment and sham con-
ditions are shown in Table 2.
As indicated by Table 2, both tDCS and pharmacother-
apy compared to the sham condition, were effective in
reduction of worry. The level of worry in the treatment
groups was significantly reduced in post-treatment and
follow up stage compared to the pre-treatment stage. Re-
garding anxiety, both tDCS and pharmacotherapy com-
pared to the sham condition were effective in reduction
of anxiety yet this effectiveness was not statistically sig-
nificant. In depression, tDCS rather than the sham condi-
tion was effective in treatment of depression, yet between-
group effects of pharmacotherapy were not significant.
Also, in post-treatment and follow up stages compared to
pre-treatment stage, the level of depression in tDCS was sig-
nificantly reduced.
5. Discussion
According to the present research, tDCS was an effec-
tive and efficient treatment for patients with generalized
anxiety disorders. There were significant improvements in
worry (PSWQ), anxiety (HARS), and depression (HDRS) in
the experimental groups when compared with the sham
condition. Another result of the current research showed
that the effectiveness of pharmacotherapy in reducing
worry and tDCS in reducing depression was significant.
However, in the anxiety variable, there were no significant
differences between the 2 treatments. In summary, the re-
sults of the present research showed that both tDCS and
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Figure 1. Comparison Between Effectiveness of Pharmacotherapy, tDCS and Sham
Condition Therapy on Treatment of Worry, Depression, and Anxiety in Generalized
Anxiety Disorder
pharmacotherapy were effective in treatment of anxiety,
depression, and worry compared to the sham condition.
Also, the comparison of these 2 treatments showed that the
effectiveness of tDCS on depression and pharmacotherapy
on worry was more and had equal effect on treatment of
anxiety, and there were not significant differences. The cur-
rent results were consistent with previous researches that
showed the effectiveness of tDCS on worry (15), anxiety (25),
and depression (26). Brennan, McLoughlin, O’Connell,
Bogue, O’Connor, and McHugh (27) showed that tDCS was
effective in treatment of depressive symptoms. The studies
of Kar and Sarkar (28) showed that the use of brain electri-
cal stimulation was effective in treatment of anxiety. Re-
cent researches with the aim of changing the prefrontal
cortex and making an equilibrium between activity of left
and right prefrontal cortex, have shown the significant ef-
fect of brain direct current stimulation on reduction of
symptoms of depression disorder (29).
The novelty of the current research was that tDCS ther-
apy could have effectiveness as much as pharmacotherapy,
and in depression cases has even more effectiveness than
pharmacotherapy. Conducting more research in the fu-
ture with more samples could clarify this effectiveness yet
what is indisputable is that tDCS is a non-invasive treat-
ment and without side effects compared with pharma-
cotherapy and its use in clinics on patients, who are resis-
tant and do not have the tendency to use pharmacother-
apy, could be an appropriate treatment for anxiety disor-
ders.
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Table 1. Summary of Descriptive Statistics of Three Measures of Variables in Pre-Post, Post-Test, and Follow Up
Group Pre-Treatment Phase (M/SD) Post-Treatment Phase (M/SD) FollowUp Phase (M/SD)
tDCS Pharmacotherapy ShamGroup tDCS Pharmacotherapy ShamGroup tDCS Pharmacotherapy ShamGroup
Worry 47 (6) 46 (8.57) 46 (9.01) 38.33 (6.05) 29.16 (6.30) 46.66 (8.31) 38.66 (4.80) 31.66 (4.08) 46.50 (8.87)
Anxiety 44.33 (5.50) 44 (8.69) 42.83 (13.10) 36 (3.57) 35.33 (7.06) 43.33 (12.89) 37 (4.09) 36.50 (5.43) 44.16 (13.31)
Depression 38.66 (9.26) 38.50 (4.59) 41 (8.48) 26.50 (5.04) 35.33 (3.93) 40.50 (8.18) 26.50 (3.97) 34.33 (4.50) 41 (7.37)
Table 2. The Result of Analysis of Variance with Repeated Measure of Three Measurements of Study Variables
Variables Conditions Source of Changes SS df MS F P Value Eta Square
factor 743.44 2 371.72 69.79 0.001 0.823
factor× group 537.44 4 134.36 25.22 0.001 0.771
Worry Inter-group error 159.77 30 5.32
group 1046.44 2 523.38 3.71 0.045 0.331
Between-group error 1505.44 10 150.544
factor 309.00 1.44 214.355 49.661 0.001 0.768
factor× group 210.33 2.88 72.59 16.90 0.001 0.693
Anxiety Inter-group error 93.33 21.62 4.31
group 254.33.44 2 127.167 0.536 0.596 0.067
Between-group error 3557.833 15 237.189
factor 345.148 2 172.547 28.429 0.001 0.655
factor× group 304.741 4 76.185 12.550 0.001 0.626
Depression Inter-group error 182.11 30 6.070
group 952.259 2 476.130 4.196 0.036 0.359
Between-group error 1701.889 15 113.459
5.1. Conclusion
In conclusion, the results of the present research
showed that tDCS by using anode electrode on contralat-
eral deltoid and cathode electrode on F4, to decrease worry,
anxiety and depression symptoms, in GAD patient is a safe,
convenient, and an a inexpensive method. Also, a few stud-
ies have been done to investigate the impact of brain stim-
ulation on GAD patients; this study might be practical for
therapists to combine their therapies with non-invasive
brain stimulation in order to increase beneficial effects of
tDCS.
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